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Abstract 
Background: Meningococcal disease (MD) is a major cause of meningitis and sepsis 
worldwide, with a high case fatality rate and frequent sequelae. Neisseria meningitidis 
serogroups A, B, C, W, X and Y are responsible for most of these life-threatening 
infections, and its unpredictable epidemiology can cause outbreaks in communities, with 
significant health, social and economic impact.  Currently, serogroup B is the main cause of 
MD in Europe and North America and one of the most prevalent serogroups in Latin 
America. Mass vaccination strategies using polysaccharide vaccines have been deployed 
since the 1970s and the use of conjugate vaccines has controlled endemic and epidemic 
disease caused by serogroups A, C, W and Y and more recently serogroup B using 
geographically-specific outer membrane vesicle based vaccines.  Two novel protein-based 
vaccines are a significant addition to our armamentarium against N. meningitidis as they 
provide broad coverage against highly diverse strains in serogroup B and other groups. 
Early safety, effectiveness and impact data of these vaccines are encouraging.  These novel 
serogroup B vaccines should be actively considered for individuals at increased risk of 
disease and to control serogroup B outbreaks occurring in institutions or specific regions, as 
they are likely to save lives and prevent severe sequelae. Incorporation into national 
programs will require thorough country-specific analysis. 
Key words: Neisseria meningitidis, epidemiology, meningococcal serogroup B, 
meningococcal vaccines, outbreaks  
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Brief overview of meningococcal infection/disease  
Meningococcal disease (MD) is a major public health problem and remains a leading cause 
of meningitis and sepsis in many countries1,2  Case fatality rates (CFR) reach 10-20% 
despite aggressive treatment, 10-20% of survivors will develop major long-term sequelae, 
including deafness, neurological deficit, seizures, limb amputation, and up to 36% of 
survivors may have one or more deficits in physical, cognitive, and psychological 
functioning1–3.  MD occurs in all age groups, although incidence rates are highest in young 
children and teenagers.  MD is mostly sporadic with seasonal variations, with occasional 
epidemics in large regions or smaller outbreaks in specific settings, which occur at rather 
unpredictable intervals.  During these epidemics an increased number of cases usually 
occurs among adolescents and young adults 4,5.  
Neisseria meningitidis (N. meningitidis) is a Gram-negative, aerobic, encapsulated, non-
mobile diplococcus, belonging to the Neisseriaceae family.  The antigenic composition of 
the polysaccharide capsule defines 12 serogroups: A, B, C, H, I, K, L, W, X, Y, Z and E6.  
Currently, six serogroups, A, B, C, Y, W and X, are responsible for virtually all cases of 
disease reported worldwide1,2,4,5.  Meningococci are also classified into serotypes and 
serosubtypes according to the antigenic composition of the outer membrane proteins 
(OMP) PorB and PorA, respectively.  Meningococci can exchange genetic material 
encoding for capsule synthesis, modifying the capsular antigenic composition of a specific 
strain.  Antigenically distinct strains due to allelic replacement of the siaD gene can lead to 
outbreaks7–10.  Genetic multilocus sequence typing targeting polymorphisms within 
multiple genes, polymerase chain reaction, and whole-genome sequencing are currently the 
most widely used methods to detect and characterize meningococcal strains5,6.  
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Meningococci infect only humans and are transmitted from person to person by aerosolized 
or direct contact with respiratory secretions or saliva.  Acquisition of meningococci can 
lead to transient carriage, persistent colonization, or result in invasive disease.  Most 
carriers will remain asymptomatic with the microorganism in their nasopharynx throughout 
their lifetime; invasive MD is a rare outcome of meningococcal infection.  For most 
individuals, carriage is an immunizing process eliciting protective antibodies11,12. 
Asymptomatic nasopharyngeal carriage of N. meningitidis is common, with a population 
prevalence of approximately 5-10% in non-epidemic settings.  Carriage prevalence varies 
with age, being low during the first years of life, increasing in teenagers and young adults 
when rates of up to 20-50% are reported, followed by a decline during adulthood11–13.  
Major differences in meningococci phenotypic and genotypic distribution between invasive 
and carriage strains are usually observed, with only a small proportion of carriage strains 
representing hyper invasive lineages.  Carriage rates of meningococci can be considerably 
higher in outbreak situations, household contacts of people with MD and in closed 
institutional settings, particularly in military personnel11,12.  Most carriers have relatively 
few organisms detectable with a minority having much larger numbers at any one time14. 
Several host-, organism- and environmental-factors have been associated with an increased 
risk for MD.  Deficiencies in the common complement pathway (e.g., C3, properdin, Factor 
D, Factor H, or C5–C9), eculizumab therapy, functional or anatomic asplenia (including 
sickle cell disease), chronic underlying illness, infection with the human immunodeficiency 
virus12, preceding viral infections (particularly influenza), household crowding, men who 
have sex with men, microbiology profession, active and passive smoking, and bar 
attendance, are all risk factors for meningococcal disease12,15.  
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Criteria used for case definition of MD vary from one place to another, limiting the 
reliability of comparisons of incidence rates among different regions.  The European Centre 
for Disease Prevention and Control (ECDC) surveillance network considers a case of 
invasive meningococcal disease confirmed when at least one of the following criteria is 
met: isolation of/or detection of N meningitidis nucleic acid in a normally sterile site; N 
meningitidis detection in cerebrospinal fluid (CSF) by antigen detection test; or 
visualization of a Gram negative diplococci in CSF16.  In the United States of America 
(USA), as well as in South Africa, a case is confirmed if the bacteria is isolated from a 
specimen obtained from a normally sterile site17,18.  In Australia and Canada the criteria 
includes nucleic acid amplification from a usually sterile site19,20.  In Latin America, despite 
the lack of uniform criteria across countries, the Pan American Health Organization 
includes confirmed cases (either detection of bacterial antigen(s) in CSF or positive culture 
laboratory proven), probable (suspected case plus turbid CSF or link to a confirmed case), 
and suspected cases (sudden onset of fever plus meningeal sign or petechial or purpuric 
rash)21.   
MD occurs worldwide, but there are marked geographical differences in incidence and 
serogroup distribution22.  In North America, serogroups B (MenB), C (MenC) and more 
recently Y (MenY) have been the main serogroups causing MD, whereas in Africa, 
serogroup A was the main cause of epidemics until 15 years ago when serogroups C, W 
and X emerged22,23.  In Europe, serogroups B and Y, and more recently W (MenW) in some 
areas have predominated, although serogroup C remains prevalent in some countries 
lacking meningococcal C conjugate (MCC) vaccination programs22,24.  In Latin America 
MenB, MenC and, during the past decade, MenW are currently responsible for the majority 
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of reported MD cases21.  Serogroups A, B, C, Y, and W have all been present, without 
apparent particular predominance in Asia.  In Australia and New Zealand MenB has 
predominated during the last decades. However, in 2016, MenW became the predominant 
meningococcal serogroup in Australia25–27.  
Despite the availability of safe and effective meningococcal conjugate vaccines against 
serogroups A, C, W and Y for several years, only recently two serogroup B recombinant 
protein meningococcal vaccines were licensed and recommended for prevention of 
serogroup B meningococcal disease (B-MD) across different age groups	   in several 
countries.  The aim of this article is to describe the global burden of B-MD, briefly review 
the data on vaccines development, and “real world” experience with these vaccines, 
including the first estimates of effectiveness, safety and impact data based on the as to yet 
rather limited use of these vaccines in routine immunization programs and for outbreak 
control. 
 
Serogroup B meningococcal disease, an ever changing, unpredictable epidemiology 
Incidence rates (IR) of B-MD have declined during the past years, in the absence of any 
vaccine intervention.  A recently published systematic review reports an average rate 
ranging from 0.01 to 4.26 per 100,000 population, with a decreasing overall trend, 
particularly in countries where data collection is more consistently collected data (figure 
1)28.  From 2000 to 2015, only two countries, New Zealand and Ireland, reported mean 
annual IR of B-MD disease above 2/100,000 habitants per year.  Australia, Iceland, 
Netherlands and UK report IR from 1-2/100,000, while the remaining countries report rates 
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< 1/100,000.  Case -fatality ratios ranged from 3% to 10% in most countries.  Three major 
hyper-invasive genotypes (clonal complex (cc) 32, cc41/44, and cc269) were responsible 
for most endemic B-MD cases globally28.  In 2014, 2,760 confirmed cases of invasive MD 
were reported in Europe, with highest IR in infants (10.1 cases per 100,000).  Serogroup B 
was responsible for most reported cases (64%), while MenC was more prominent in 
countries that had not implemented MCC vaccination22,24.  In the USA, 375 cases of MD 
(IR 0.12/100,000) and 60 deaths (CFR 16%) were reported in 2015, with serogroup B 
responsible for approximately 60% of the cases among children younger than 5 years of 
age29.  In Canada, serogroup B remains as the predominant serogroup, particularly at 
younger ages.  However, increased incidence of serogroup W has been reported recently30.  
In Latin America, incidence rates of MD have varied widely during past years, from < 0.1 
cases per 100,000 in Mexico, Peru, Paraguay and Bolivia, to 2/100,000 in Brazil, with the 
highest incidence rates observed in infants.  Misnotification and poor surveillance in some 
countries of the region, especially in those with low IR, are issues that introduce some bias 
in the analysis of these data.  Regarding serogroup distribution, serogroups B and C are 
responsible for the majority of cases reported in the region, with an increased number of 
serogroup W cases associated with the cc ST-11, reported in Argentina and Chile.  The 
highest incidence rates of B-MD disease in the region are reported in Argentina, Brazil, 
Chile, Colombia and Uruguay31.  In New Zealand, during the 2000s a serogroup B 
epidemic occurred with incidence rates reaching 17.4 per 100,000 total inhabitants in 2003.  
A tailor-made, strain-specific serogroup B vaccine using outer membrane vesicles (OMV) 
from cc ST-41/44 (MeNZB®, Norwegian Institute of Public Health and Novartis Vaccines) 
was introduced in 2004.  A significant decrease in incidence rates of the B-MD epidemic 
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strain during the first years after program implementation was observed, leading to 
discontinuation of vaccination32.   
In Asia, although the true burden of MD is unknown, reported IR are low in all countries 
although B-MD has been reported causing sporadic cases in Bangladesh, China, India, 
Indonesia, Japan, Malaysia, the Philippines, Singapore, Taiwan, and Thailand28.  However, 
the degree of underreporting has not been fully evaluated in this and to some extent also in 
other regions. Few studies and low numbers of publications, poorly implemented 
surveillance programs, lack of guidelines and standard case definitions, and inappropriate 
laboratory methods are significant issues in Asia, with some notable exceptions22,33,34. 
In Africa, endemic B-MD disease has been reported only in Ghana and South Africa, with 
almost no B-MD cases reported from the remaining countries. In the 26 countries of the 
sub-Saharan meningitis belt the incidence of serogroup A decreased dramatically after 
MenAfriVac® introduction; serogroup W and more recently C have become predominant35.  
 
Outbreaks of B-MD Disease 
A small fraction of reported MD cases occur within the context of meningococcal 
outbreaks. They are unpredictable and associated with severe outcomes, which can be 
emotionally devastating within affected communities or institutions. According to the USA 
Centers for Disease Control and Prevention (CDC), an outbreak is defined by the 
occurrence of at least three confirmed or probable primary cases of MD caused by the same 
serogroup in ≤3 months, with a resulting primary attack rate of ≥10 cases per 100,000 
population36.  This definition is used primarily to guide vaccination and antibiotic 
intervention recommendations.  However, in organization-based outbreaks, such as those 
that occur in universities, schools, daycare centers, occupational training centers, or 
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correctional facilities, with three or even just two cases of disease, rates may reach >10 
cases/100,000 population.  In such situations, public health officials may also consider 
vaccination after only two primary cases are identified. In figure 2, we depict outbreaks 
reported to the World Health Organization (WHO) from 2012 to 2017; most were caused 
by serogroup B, affecting high schools, colleges and universities.  
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Group B Meningococcal Vaccines 
The first attempts to prevent MD by vaccination occurred at the beginning of the twentieth 
century with whole cell formulations, which were used until sulfa chemoprophylaxis 
became available37.  Development of polysaccharide vaccines began in the 1960s with the 
hallmark finding that susceptibility to invasive disease was associated with low levels of 
serum bactericidal antibodies (SBA) to meningococci38.  Due to the relatively low 
incidence of endemic meningococcal disease, vaccine efficacy studies would require 
hundreds of thousands of subjects.  Accordingly, the WHO has accepted an SBA titer using 
exogenous human complement (hSBA) > 1:4 as correlate of protection39,40.  Meningococcal 
A, C, W and Y conjugated polysaccharide vaccines have been developed and licensed, in 
mono, bivalent and multivalent formulations since the year 200040.  The capsular 
polysaccharide of serogroup B strains is poorly immunogenic due to its antigenic structure, 
which resembles glycosylated neural cell adhesion molecule which is expressed in the 
developing human brain; as well as immunological tolerance, this antigenic mimicry with 
human tissue raises the potential for the induction of autoimmunity34.  For this reason, 
serogroup B vaccine antigen selection strategy moved towards OMPs, mainly porA and 
porB, which can elicit strain-specific protective antibodies measurable in human sera.  
These OMPs were first obtained from OMVs generated in laboratory conditions and shed 
during the growth process of N. meningitidis.  They mimic the structure of the outer 
membrane of the specific meningococcal B strain, are soluble and induce a robust immune 
response by presenting proteins in their native structural conformation34,40–43.  OMV 
vaccines were successfully used in specific clonal outbreaks in Cuba, Norway and New 
Zealand34,39,40,43,44.  However, monovalent OMV vaccines elicit highly specific immune 
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responses to the PorA subtype, and these subtypes are highly variable among different 
isolates of N. meningitidis circulating worldwide.  
Studies showed disparity in population immunogenicity, effectiveness and persistence 
between OMVs, mainly in infants and toddlers39,40,44.  Multivalent PorA candidates were 
evaluated, but SBA responses and direct bactericidal activity against strains varied 
depending on the PorA type40.  Thus a universal OMV vaccine was not deemed 
feasible34,39,40.  Using genomic based approaches, specific OMPs have been synthesized 
and used with the aim of broadening strain coverage as they should be functionally 
relevant, immunogenic, and more conserved among geographically diverse strains, 
compared to OMVs34.  For MenB, the antigenic variability and level of surface expression 
of OMPs presents a challenge for determining vaccine coverage against the myriad of 
circulating strains34,45,46.  These novel B-MD vaccines, denominated 4CMenB (Bexsero®, 
GlaxoSmithKline (GSK)) and bivalent rLP2086 (Trumenba®, Pfizer) are now licensed in the 
USA, Canada and Europe as well as in other countries.   
The multicomponent vaccine 4CMenB has three primary recombinant antigens obtained 
using an approach denominated “reverse vaccinology”, based on DNA sequence data from 
serogroup B strains which identified surface-exposed proteins, with capacity to induce 
bactericidal antibodies in animal models42,47: factor H binding protein (fHbp), subfamily 
B/v1, neisserial adhesin A (NadA), and Neisseria heparin binding antigen (NHBA).  In 
addition it includes the OMV expressing PorA from the New Zealand strain, NZ PorA 
P1.4.  Native OMVs have a potential advantage, as detergent extraction solubilizes 
phospholipids and membrane-associated lipoproteins that enhance the immune response48.  
The selection of the OMV-NZ strain was based on the experience from the OMV-based 
vaccine MeNZB®, which proved to be safe and efficacious in the control of the clonal 
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MenB epidemic in New Zealand42, in combination with immunogenicity results from a 
study performed in healthy adults49.  The latter provided evidence that the addition of 
OMV-NZ to the other three antigens (fHbp, NadA and NHBA) enhanced the coverage 
against ST-41/44 complex/lineage III strains.  Pivotal phase II/III studies are summarized in 
table 1.  The vaccine has been demonstrated to provide a robust priming and anamnestic 
immune response in all age groups against four laboratory serogroup B reference strains 
chosen to measure responses against each antigen included in the vaccine, even using a 
reduced vaccine schedule in young infants50, and allows concomitant administration with 
other routine vaccines.  Concomitant administration of MCC-CRM vaccine with 4CMenB 
was performed in Brazilian infants at 3 and 5 months with a booster at 12 months of age.  
Although the geometric mean titers against meningococcal serogroup C were lower among 
subjects that received 4CMenB, the proportion that achieved seroconversion was identical, 
and considered sufficient to MenB, after primary and booster vaccination.  Reactogenicity 
was higher for concomitant vaccines administration, but no safety concerns were 
identified51.  The safety profile of 4CMenB has been considered acceptable, although it is 
reactogenic.  Injection site pain/tenderness and fever in infants, and injection site pain, 
malaise, and headache in adolescents are relatively common52-54.  Among infants, side 
effects can become a cause for emergency room visits, hospitalizations, and increase 
antimicrobial misuse55,56.  The European Medicines Agency (EMA) approved 4CMenB in 
2013 for infants from 2 months of age, as a three-dose primary schedule followed by a 
booster in the second year of life, and a two-dose schedule in children, adolescents and 
adults57.  The USA Food and Drug Administration (FDA) approved the vaccine in 2015 as 
a two-dose schedule for use in individuals aged 10 through 25 years of age58.  This vaccine 
was introduced into the United Kingdom (UK) universal immunization schedule at 2, 4 and 
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12 months of age in 201559,60.  Other countries with approval include Australia, Canada, 
Chile, Brazil, and Argentina.  
The bivalent rLP2086 includes two variants of the surface-exposed fHbp protein.  This 
protein segregates into two genetically and immunologically distinct subfamilies, A (A05) 
and B (B01), which have been found to be expressed in nearly all strains isolated from 
invasive disease caused by serogroup B in reference laboratories in Europe and USA41.  
Clinical studies included more than 15,000 subjects aged 10 through 25 years of age in 11 
clinical studies conducted in the US, Europe, Canada, Chile, and Australia.  These studies 
demonstrated that the bivalent rLP2086 elicits SBA capable of killing serogroup B strains 
expressing fHbps that are homologous and heterologous to vaccine components.  In phase 
II trials, two doses of rLP2086 provided robust immunogenicity in healthy adolescents 
which increased after a third dose61–64 (Table 1).  The vaccine can be administered to 
adolescents concomitantly with other licensed vaccines, including ACWY meningococcal 
(MenACWY) conjugate vaccine, quadrivalent human papillomavirus vaccine (HPV), 
reduced diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated polio virus 
vaccine (TdaP-IPV) and tetanus toxoid, reduced diphtheria toxoid and acellular pertussis 
vaccine adsorbed (Tdap)64-66.  The vaccine has been reported to be well tolerated in clinical 
trials, although mild to moderate adverse reactions such as pain, redness and swelling at the 
site of injection are common, followed by headache, fatigue and fever as systemic 
reactions62,64,67,68.  The vaccine was approved by the FDA in 2014 for use in adolescents 
and young adults aged 10–25 years in a three-dose schedule, 0, 1-2 and 6 months or a two-
dose schedule, 0 and 6 months, depending on the risk of exposure and the patient’s 
susceptibility to meningococcal serogroup B disease65.  EMA approved the vaccine in 2017 
for subjects aged 10 years and older, in a two-dose schedule administered at a 0 and 6 
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months interval, or in a three-dose schedule, 0,1-2 and 6 months.  At the time of writing, 
the vaccine had not been submitted for use in children below 10 years of age.  A booster 
dose should be considered following either dosing regimen for individuals at continuing 
risk of invasive MD66.  
4CMenB in infants is associated with higher rates of local and systemic reactions when 
given with other routine infant vaccinations, with a significantly increased the risk of 
serious adverse events (SAEs) compared with control vaccines (odds ratio 4.36 [95% CI 
1.05–18.1]; p=0.043), but the incidence of potentially vaccine-related acute SAEs in 
individuals receiving 4CMenB was low (5.4 per 1,000 individuals)69.. Fever, local 
tenderness, erythema and pain have been the most commonly reported adverse effects 
across the studies.  Fever was seen up to 41%, usually on day 1, returning to normal by day 
3.  Prophylactic administration of paracetamol before and 4–6 hours after vaccination 
significantly reduces post vaccination fever without affecting immunological responses70.  
Severe erythema, swelling, or induration were seen in < 1%, with a peak on day 1, with a 
steep decrease on day 2 and lower incidence after booster (table 1).  The most commonly 
reported SAE were febrile convulsions, Kawasaki disease and arthritis.  Seven cases of 
febrile seizures occurred after vaccination with 4CMenB, with a rate of 0.1 events/1,000 
vaccination visits in the 4CMenB study arms, mainly during primary infant series, on the 
day of or day following vaccination69,71.  Arthritis was reported in 4 subjects, three of them 
after 4CMenB vaccination69.  Finally, Kawasaki disease was reported in 7 subjects (1 in the 
control group and 6 in the 4CMenB groups) in the pre-licensure studies.  The onset varied 
from 1 day to 5.5 months after vaccination and all cases were adjudicated by a panel of 
outside experts and estimated annual incidence post-vaccination was 72 (95 % CI 23–169) 
per 100,000 subject-years after 4CMenB versus 56 (95 % CI 1–311) after control vaccines, 
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which were similar to rates of other rare adverse events observed in other pre-licensure 
clinical programs46,57,58,69,71, however, post-licensure safety surveillance will be of 
paramount importance.  In phase 1/2 study in infants, rLP2086 was considered not 
acceptable due to the high fever rate experienced (64-90%) in the 20 and 60 µg groups so 
formulation were discontinued72.  
In adolescents headache and fatigue were the most common systemic events for both 
vaccines.  Fever was as infrequent as 4%.  Local and systemic reaction rates were similar 
after each injection and did not increase with subsequent doses, but remained higher than 
placebo.  Pain was most frequently reported in pre-licensure studies with 4CMenB than 
rLP2086 recipients (86% versus 9,9%), however, an observational study of adverse events 
during a college outbreak after a campaign vaccination with rLP2086 published recently, 
reported that the most commonly event following vaccination was injection site pain, 
reaching 77,6% after the first dose, but only 4% was considered severe54,57,58,62,65-68,73,74. 
Persistence of bactericidal antibodies among infants vaccinated with 4CMenB wanes at 12 
months of age although remaining higher than baseline; the magnitude of waning varied for 
each antigen being less for NadA and fHbp75,76.  Actually, at 12 months of age, after three 
priming doses and before the booster dose, the proportions with hSBA titers ≥ 1:5 for fHbp 
was 57%-85%, ≥ 96% for NadA and between 18-35% for PorA.  Following a 12-month 
booster-dose ≥ 95% of previously immunized participants had titers ≥1:5 for all strains, 
independent of the priming schedule interval75.  Similar results were observed in a study 
that assessed the persistence of immune responses after one year in participants vaccinated 
as infants, and responses in vaccine-naïve children.  Antibodies waned over 12 months, 
particularly against strain NZ98/254 (PorA), although higher GMTs were observed 
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compared to the unvaccinated control group76.  Even in children vaccinated with 5 doses, at 
2, 4, 6, 12 and 40 months of age, waning of immunity was observed by 5 years of age, with 
protective antibodies ranging from 44% to 88% against matched strains and from 13% to 
81% against mismatched strains77.  In children vaccinated between 12 and 24 months of 
age waning of hSBA titers was also observed by 4 years of age, with a robust response after 
a booster dose at 40 months of age78.  For adolescents, protective hSBA titers 18-24 months 
after completing a two-dose vaccine schedule with the 4CmenB vaccine were detected in 
64% for all vaccine-related antigens and in 85% for two of the three target antigens; a third 
dose did not provide additional benefit79.  
Antibody persistence after the bivalent rLP2086 vaccine was assessed in an open-label, 
follow-up study of subjects previously enrolled in a primary study.  The decline in antibody 
levels among individuals 11 to 18 years of age, 4 years after a primary series on a 2 or 3-
dose schedules, follows a similar pattern.  A decrease in response was evident for all test 
strains from month 6 to month 12, followed by a plateau thereafter up to month 48.  
Subjects achieving protective hSBA titers for four fHbp variants strains combined ranged 
from 15.7% to 18.2%.  Taking into account the importance of circulating serum antibodies 
to maintain protection against invasive meningococcal disease, the persistence data suggest 
that booster doses would be required to maintain long-term protection.  All subjects showed 
a robust immune response one month after a booster dose for different fHbp variants 66,74,80 
The capacity of these protein based vaccines to prevent acquisition of serogroup B carriage, 
or otherwise to interrupt transmission and thus provide herd protection, once targeting the 
age groups responsible for carriage, is currently unclear.  In UK university students no 
significant difference in serogroup B carriage prevalence was detected between the 
	   19	  
4CMenB vaccinated and non-vaccinated control groups one month after the second dose, 
however three to twelve months after vaccination, meningococcal carriage prevalence was 
reduced for all N meningitidis and capsular groups BCWY in vaccinated individuals, 
although to a lower extent compared to carriage reduction conferred by ACWY conjugated 
vaccines81.  Another meningococcal carriage study was performed in 3,082 students at the 
Oregon University following a meningococcal B vaccination campaign with both novel B-
MD vaccines, in response to an outbreak in 2015.  After 4 carriage surveys over a period of 
11 months, no impact on meningococcal carriage was shown, suggesting that novel B-MD 
vaccines may not provide herd protection in the context of an outbreak response82.  Similar 
experience was seen in Rhode Island after a mass vaccination campaign in a college with 
rLP2086, reinforcing the need for high vaccination coverage to protect vaccinated 
individuals and chemoprophylaxis for close contacts during outbreaks83.  A recent study 
performed in Spain found that the potential impact of the 4CMenB vaccine on Spanish 
asymptomatic carrier strains appears to be due to the NHBA antigen84. 
Effectiveness of the protein-based vaccines will depend on strain coverage, which can be 
estimated from hSBA responses performed with a panel of serogroup B strains 
representative of antigenically and epidemiologically diverse invasive disease isolates. 
However, the logistical limitations associated with the use of hSBA led to the development 
of alternative nonfunctional assays to infer vaccine breadth of coverage, such as the 
meningococcal antigen typing system (MATS) and/or the meningococcal antigen surface 
expression (MEASURE) flow cytometry-monoclonal antibody based method.  4CMenB is 
conservatively estimated to provide 66–91% coverage against serogroup B strains 
worldwide46,85 based on analysis of pooled sera from vaccinated infants that meet a 
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minimum threshold of reactivity in the MATS ELISA and/or contain the PorA 1.4 antigen.  
For the bivalent rLP2086, MEASURE uses immune sera specific to a surface-expressed 
epitope common to variants within both fHbp subfamilies included in the bivalent 
vaccine50; at the time of writing, testing of strains had not yet been published.  For 
rLP2086, pairwise identity analysis between a test strain and fHbp sequences from the same 
subgroup indicate high sequence conservation, estimating a coverage from 84.8% to 
88.5%86.   In the future, these types of analysis may provide temporal and regional data for 
serogroup B vaccine policy related decisions.  The meningococcal antigen typing system 
(MATS) could potentially underestimate coverage, as it was shown in a study when MenB 
isolates from England and Wales were assessed, reaching a 73% to 88% coverage45–48. 
Another study performed in the United Kingdom (UK) following 4CMenB introduction in 
infants showed >80% vaccine-mediated protection against all current MenB strains 
circulating in the country87,88.  This could be explained by the existence of cross-protective 
epitope on fHbp variant 1.1 that elicit bactericidal neutralizing antibodies to antigen-
binding fragment 1A12 which is cross-reactive and targets an epitope highly conserved 
across the repertoire of three naturally occurring fHbp variants89   
These vaccines may prove to be effective against non-serogroup B strains due to cross-
protection provided by the highly conserved antigenic proteins included in the vaccines85,90, 
as has been reported in the UK in relation with the hyper virulent Neisseria meningitidis 
serogroup W strain circulating, especially in infants.  The technique to predict non-MenB 
vaccine strain coverage using MATS positive bactericidal threshold has not yet been 
validated.  Therefore to evaluate the impact that 4CMenB vaccination may have on non-
serogroup B disease SBA activity of sera from vaccinated subjects to kill meningococcal 
strains belonging to serogroups C, Y, and W isolates have been used, provided by the 
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reference laboratories in UK, Germany, France and Brazil.  An overall proportion of 
serogroups C, Y and W strains killed at hSBA titers ≥8 ranged from near 45% to 90% 91.  
Another study, performed by Gorla et al, with strains representing the total MD cases 
occurring during 2012 in Brazil showed differences between adolescents and infants 
coverage with a 100% coverage for MenW and MenY, but no coverage for MenC strains 
tested with pooled infant immune sera and 100% for MenC, 86% for MenW, and 67% for 
MenY using adolescent immune sera92.  Regarding serogroup X, the same analysis was 
performed for strains from Niger, Chad, Burkina Faso and France, suggesting coverage for 
african isolates but not for X isolates from France which expressed unrelated fHbp sub 
variants belonging to variants 2 and 393.  The universal presence of full-length NadA genes 
within currently circulating MenW cc 11 clones, English/Welsh strain, indicates that 
4CMenB may afford protection.  Tested invasive MenW:cc11 isolates from patients 4 
months to 91 years old in England and Wales during 2011–2012 with pooled sera from 
vaccinated children showed that hSBA titers were high (>1:32) against all MenW 
isolates8,90.  In addition, 4CMenB variants for NadA and NHBA, unless different from 
these alleles peptides in MenW English/Welsh strain, can induce cross-protection, and 
collaborate in the complement-mediated bactericidal killing90.  
Considering the commonly accepted threshold of €50,000 per QALY, novel MenB 
vaccines are not expected to be cost-effective in a National Immunization Program (NIP) 
unless a considerable increase in MenB incidence occurs or new information that clarify its 
role in herd protection or persistence of immune protection becomes available.  Infant 
vaccination could further reduce the burden of disease and prevent more deaths as 
compared to adolescent schedules, but at a substantially higher cost; so cost- effectiveness 
and feasibility of introducing a novel MenB vaccine into a NIP needs to be based on 
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country-specific assessments94–100.  This issue requires further analysis and studies, which 
should be obtained and complemented from the UK experience.  
Regarding vaccines comparison, 4CMenB and rLP2086 are both proteins based vaccines, 
developed using different strategies, aiming to provide broad strain coverage.  4CMenB 
includes three antigens (including only one subtype of fHbp) in addition to OMV while 
rLP2086 includes the two main subtypes of fHbp.  Comparisons of potential strengths and 
weaknesses have to be made with caution as different techniques have been used to 
evaluate these vaccines.  Face to face efficacy studies are not available and thus vaccines 
cannot be fairly compared.  Immunogenicity studies use different antigens and criteria and 
thus for are not comparable.  For rLP2086 vaccines protective antibody titers surpass 73% 
and 80% after two or three doses respectively in adolescents74 and for 4CMenB, protective 
levels ranged from 99% to 100% for PorA, fHbp, and NadA antigens54.  Only the 4CMenB 
vaccine was licensed in infants with composite antibody levels reaching 85–95 % after the 
primary series with three doses57.  Studies of antibody persistence revealed a bactericidal 
activity lasting 18-24 months in over 64% of adolescents for all three tested 4CMenB 
vaccine-related antigens79 and a sharp decline for antigens expressing fHbp subfamilies A 
and B ranging from near 25% to 60% in the percentage of subjects with protective 
antibodies since 12 to 48 months after priming with rLP208680; indicating that immunity 
wanes for both vaccines.  In children, a recently published meta-analysis assessed 4CMenB 
persistence of immunogenicity against the four reference strains finding that it remained 
high 6 months after the booster dose just for NadA and NHBA reference strains and then 
decreased till values obtained before booster dose69,75,78  
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The potential for cross-protection against non-B meningococcal strains has been described 
for 4CMenB, specifically for C, W, Y and X strains, but not yet for rLP2086.  For both 
vaccines, the impact of vaccination on nasopharyngeal carriage is uncertain. 4CMenB has 
demonstrated a reduction only in one study performed in UK from 3 months after dose two, 
of 18.2% on any meningococcal strain and 26.6% for capsular groups BCWY, with a 
reduction in prevalence of carriage observed over 1 year of follow-up81.  For rLP2086 no 
impact on carriage has been demonstrated, regardless the number of doses administrated 
during outbreaks in American universities and colleges82,83.  Both vaccines can be 
coadministered with other childhood or adolescent vaccinations.  4CmenB can be 
coadministered with monovalent or combination vaccines including: diphtheria, tetanus, 
acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B, 
heptavalent pneumococcal conjugate, measles, mumps, rubella, varicella, and MCC-CRM 
vaccine in infants and children; coadministration studies are not available for 
adolescents57,58.  For rLP2086 the following vaccines can be given concomitantly in 
adolescents, TdaP-IPV, quadrivalent HPV, MenACWY conjugate vaccine and tetanus 
toxoid, Tdap.  Bivalent rLP2086 vaccine is not approved for infants65,66.  Both vaccines are 
relatively reactogenic as has been described above, causing pain at the site of injection in 
adolescents and infants, and fever in infants; it is unclear if one vaccine is more reactogenic 
than the other as no head to head studies are available.  4CmenB has been included in five 
NIPs59,60,101-104 and has been used in regional programs and to control specific outbreaks105–
110, especially in colleges, while rLP2086 has not yet been incorporated into a NIP, but has 
been used in college outbreaks110–112.  Finally, both vaccines are currently of relatively high 
cost97,98,100. 
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For the investigational  vaccine against serogroups A, B, C, W and Y (MenABCWY), 
phase 2 studies performed in adolescents have showed that two or three doses are able to 
elicit a robust immune response against ACWY serogroups, at least comparable with those 
after one dose of MenACWY-CRM vaccine, and for serogroup B test strains with an 
acceptable reactogenicity and safety profile, similar to 4CMenB.  In addition, MenABCWY 
vaccine may be suitable for booster doses after priming with MenABCWY vaccine or 
4CMenB vaccine113-116.  Further clinical development is necessary but promising to give us 
the opportunity to control MD. 
 
Consideration for use of the serogroup B protein based vaccines for N. meningitidis 
outbreaks 
Massive vaccination campaigns can be implemented for outbreak control. Importantly, 
vaccination does not replace recommended chemoprophylaxis36,105,117.  Before vaccine 
implementation, appropriate surveillance systems including follow-up of close contacts 
should be available.  Ideally, the infecting strain should be characterized, but, this should 
not delay the decision regarding vaccine introduction during outbreaks36.  There is no 
current preference for one of the two available vaccines according to CDC 
recommendations and vaccine interchangeability cannot currently be endorsed118.  
 
Effectiveness and safety of serogroup B protein-based vaccines from “early adopter” 
countries/regions 
The UK experience 
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For the last several decades capsular group B endemic meningococcal disease has 
predominated in the British Isles at incidence rates that are higher than those seen 
elsewhere in Europe33.  Numerous clonal types of group B causing invasive disease have 
circulated119.  This is in contrast to some other capsular groups, notably group C in the 
1990s and group W in the second decade of the twenty first century, each of which showed 
rapid rises in incidence associated with spread of single hyper invasive clones8.  While 
these latter problems were, respectively, solved120 and, at the time of writing, are being 
tackled by widespread deployment of conjugate vaccines in the adolescent age group121, 
who are most commonly carriers and thus onwards transmitters of meningococci in the 
population, this option does not currently exist for group B. 
Accordingly, in the context of recognition that efforts to improve early diagnosis and to 
improve outcomes through more aggressive or novel adjunctive therapy were unlikely 
further to reduce case fatality rates or the frequency and severity of long term morbidity 
and buoyed by strong public and political support for action, the pediatric academic 
community in Europe engaged actively with the company developing 4CMenB and 
contributed to advancing the pre-licensure development program122. 
Following European licensure, initial evaluation of the cost effectiveness of using the 
vaccine, based on estimates of likely coverage of UK invasive strains122, cast doubt as to 
whether it would meet the stringent criteria set by the UK government for introduction of 
healthcare interventions within the National Health Service in the country60.  However, 
after further evidence was gathered, it became clear that the threshold could be met if a 
slightly modified schedule from the one specified in the product license was used and the 
vaccine was introduced for infants in September 201559.  Infants receive 2 doses at 2 and 4 
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months of age alongside other primary schedule vaccines and receive a third dose at 12-13 
months.  The uptake reported from August to December of 2017 in UK, reached 95.9% for 
one dose and 88.4% for two doses by six months of age and 87.4% for the booster dose123.  
Advice concerning routine antipyretic-analgesic use was modified to advise that 
paracetamol should be given at the time of the first two doses. 
Early ecological data comparing changes in rates of meningococcal group B disease over 
time in the immunized cohort with those in older age groups indicate that the vaccine 
induces protection more effectively than was predicted pre-implementation87.  The rates of 
uptake of the vaccine have been consistently high but concerns that its tendency to cause 
fever in many infants when given with other vaccines would lead to increases in rates of 
hospital attendance have been confirmed, reinforcing the importance of paracetamol 
prophylaxis56. 
Whether deployment of the vaccine in adolescents would reduce carriage and result in herd 
protection as seen following conjugate vaccine programs remains an unanswered question 
at the time of writing.  If 4CMenB and/or the more recently licensed bivalent fHbp vaccine 
can do this will determine whether cost-benefit thresholds can be met for their use in this 
age group.  An on-going study in South Australia (Marshall et al., manuscript submitted for 
publication) and a planned study in the UK may provide the answer. 
 
The Saguenay-Lac-Saint-Jean experience in Canada  
The Saguenay-Lac-Saint-Jean (SLSJ) region was affected by a 269 (ST-269) serogroup B 
clone with an average incidence rate of 3.4 per 100,000 person-years from 2006 to 2013, 
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which surpassed Canadian average rates by more than 10-fold (0.3/100,000). Cases were 
concentrated among individuals ≤ 20 years of age.  To control the spread of this clone, a 
massive vaccination campaign using 4CMenB according to its locally approved schedule, 
was undertaken, targeting more than 50,000 people between the ages of 2 months and 20 
years residing in, or attending an educational institution in the region109.  The vaccine 
uptake rate for one dose was 82%, but only 70% for at least two doses, mainly due to low 
uptake in older adolescents and young adults.  The vaccination campaign was estimated to 
have reduced disease incidence by 77% and new serogroup B cases have not been reported 
among vaccinees, with two cases observed among non-vaccinated adults.  An enhanced 
surveillance system was also implemented to monitor the onset of adverse events following 
immunization in real time109,124.  Fever was reported in 12% of vaccinees and was more 
frequent in young children.  Antipyretic prophylaxis (paracetamol mainly) was 50% 
effective in preventing the occurrence of fever in children less than 5 years of age but not in 
older age groups.  There was no death and no major adverse event with or without sequelae 
associated with vaccination.  During the two-year period following the immunization 
campaign in SLSJ, no IMD case was recorded among unvaccinated individuals, including 
infants, thus it seems that at least some herd effect may be occurring109.  
 
Vaccine use for control of university outbreaks in the USA 
From 2009 to 2014 five serogroup B outbreaks on college campuses were reported to CDC.	  	  
In 2013, 4CMenB vaccination campaigns were implemented in response to ongoing 
serogroup B outbreaks at the Universities of Princeton and Santa Barbara, due to sustained 
transmission during 2 academic years.  The FDA approved the use of 4CMenB before 
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national licensure under an expanded access investigational new drug protocol in December 
2013106,108.  The attack rate in Princeton was 134/100,000 among undergraduates living in 
dorms, with individual cases occurring 2 to 4 weeks apart.  The strain isolated expressed 
two of the 4 antigens (fHbp and NHBA) in sufficient quantities to suggest that 4CMenB 
might be protective108.	   	   Vaccine was offered to nearly 5,800 individuals including 
undergraduate students, faculty, staff and graduate students at increased risk of 
meningococcal disease, and spouses and caregivers of graduate and undergraduate students 
living in a dormitory with students.  Uptake was very high, reaching 95% for the first dose 
and 89% for the second dose, with approximately 5,200 individuals who received al least 
one dose106.  The rate of reported SAEs was near 2.0/1,000 vaccinees following the first 
dose and 0.2/1,000 following the second dose, with no causality related to 4CMenB 
observed108.  In the University of California at Santa Barbara outbreak, the attack rate was 
21.1/100,000; despite the fact that the strain was different from the Princeton strain, 
protection was expected from 4CMenB based on killing properties of pooled post-
immunization sera.  The target groups were similar to Princeton with nearly 20,000 subjects 
eligible and nearly 17,000 vaccinated with no cases occurring in vaccinated 
students34,108,117.	   	   Parallel to this immunization campaign, an immunogenicity study was 
performed in a subset of 607 subjects showing that 66.1% had hSBA protective titers 
against the outbreak strain125.  This result was lower than that predicted by the MATS test, 
suggesting that hSBA underestimates protective immunity.  The bivalent rLP2086 vaccine 
was administered to 3,525 subjects in Providence College and to nearly 22,0000 students in 
the University of Oregon during outbreaks occurring in 2015, achieving a 94% first dose 
uptake among eligible students.  College-associated cases were not identified during the 4 
months follow up period82,83,107,126. 
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Despite the success achieved after the widespread vaccination campaigns to control 
outbreaks of serogroup B-MD, with no further cases reported among vaccinated subjects, 
the long-term duration and breadth of protection, as well as the impact of these vaccines on 
prevention of carriage remains to be determined. 
 
Conclusions 
Rates of invasive B-MD have been declining worldwide, although in certain geographical 
areas and populations incidence rates can be particularly high. In addition, outbreaks of B-
MD occur in an unpredictable manner in a number of settings where people gather, 
especially universities. Although several possibilities were raised to explain the declining 
trend in B-MD incidence observed during the last decades, including declining smoking 
rates, changes in population immunity, bacterial virulence and a natural cyclical pattern of 
meningococcal serogroup distribution 25, reasons remain unclear. The high CFR and the 
significant sequelae in surviving individuals, as well as its potential epidemic nature are the 
main reasons for primary prevention, for which vaccination is the only effective tool. Age 
groups at highest risk are young children, especially infants under one year of age, followed 
by adolescents in areas where close contact is frequent such as university dorms in the 
USA. Meningococcal vaccines against non-serogroup B strains have been based on protein 
conjugated capsular polysaccharides targeting specific serogroups (A, C, W and Y) with 
great success. The rapid and sustained reduction in serogroup C disease rates in the UK and 
other countries after vaccine implementation into national immunization programs has been 
a significant achievement. Flexible vaccine schedules focusing not only on direct 
protection, targeting the age groups with the highest incidence rates of disease (usually 
infants), but also vaccinating the age groups that act as the reservoir for infection (usually 
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adolescents and young adults) and thus reducing carriage rates and interrupting 
transmission in the community, have proven effective for serogroups susceptible to be 
prevented by this vaccine strategy. 
The antigenic mimicry between serogroup B polysaccharide and human neural tissue 
antigens curtailed development of polysaccharide-based vaccines against this pathogen, and 
left it unprevented for decades.  The solution was found in targeting outer membrane 
proteins, first in the form of OMVs, which are a laboratory-obtained simile of the outer 
membrane (of which porins are the main antigenic target).  This vaccine proved to be 
immunogenic, protective, and effective in controlling regional outbreaks, with the caveat 
that the immune response, based on the induction of SBA, was highly strain-specific for the 
porin within the OMV.  The significant variability of porins among strains circulating 
worldwide precluded this strategy for universal vaccination.  But the proof of concept that 
protein antigen vaccines can be highly protective had been established.  Second generation 
protein-based vaccine candidates aimed to identify antigens expressed in as many 
serogroup B strains as possible in order to provide “broad strain” protection.  These 
candidates are now licensed vaccines although in a stage of post-licensing “field 
evaluation” as they were approved based on safety and immunogenicity studies and their 
use is currently limited to only one country in a routine national program, to some regions, 
and a few outbreak situations.  The fact that in all the experiences to date results have been 
encouraging is promising.  The 4 component vaccine targeting four different proteins from 
GSK (developed by Novartis vaccines) and the two component vaccine targeting the two 
subfamilies of one relevant protein, from Pfizer, elicit serum bactericidal antibodies 
although in variable quantities depending on the antigen.  It seems that antibodies to any of 
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the protein antigens in the vaccine may be sufficient to protect, but this is uncertain.  The 
exact protective effectiveness for each vaccine is thus currently unknown although for 
4CMenB it seems to surpass 85% for the first year after the primary series.  Antibodies 
wane and because MD is fulminant, depending on memory cells is not sufficient to avoid 
severe disease if a vaccinated individual is exposed several years after vaccination.  Thus, 
booster doses are likely to be needed to provide sustained individual protection.  In 
addition, the breadth of strain coverage, which seems quite inclusive based on MATS 
testing for 4CMenB (over 60% of strains) and probably also for rLP2086, will require 
persistent strain surveillance over time.  One limitation associated with both vaccines is 
their high reactogenicity profile both local and systemic, especially among infants.  Only 
one of the two vaccines, 4CmenB, has been licensed for use in infants, and increased 
medical visits and even hospitalization due to febrile episodes have been reported.  
Importantly though, this reactogenicity profile has not been associated with severe 
outcomes to date, and hopefully will be adequately dealt with through parental education, 
as we gain more experience with both vaccines.  
The two-serogroup B vaccines are a significant addition to our armamentarium against 
highly significant pathogens for humans.  The vaccines should certainly be considered for 
persons at increased risk for MD and when dealing with serogroup B outbreaks occurring in 
institutions or specific regions, as they will most likely save lives and prevent severe 
sequelae.  Incorporation into national programs will require thorough analysis such as has 
been done in the UK; the world is once again watching closely the vaccine experience of 
this country (a post licensure field experiment) which will be of significant help to other 
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countries with relatively high prevalence rates, who may be considering the incorporation 
of a serogroup B vaccine for the benefit of their populations. 
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Figures legends 
 
Figure 1. Annual incidence per 100,000 people of serogroup B invasive meningococcal 
disease worldwide from Jan 1, 2000, to March 1, 2015 (28).  
 
Footnote: authorization obtained by Lancet Infectious Diseases, license number 
4253831337542 
 
Figure 2. Meningococcal Outbreaks reported to the WHO from 2012 to 2017.  
 




Oregon: Oregon State University, 3 cases, 
2016-2017 
Oregon: Oregon State University, 7 cases,  
1 death, 2015 
California: California University at Santa 
Barbara, 4 cases, 2013 
California: Santa Clara University, 3 cases, 2016 
Wisconsin: University of Wisconsin, 3 cases, 
2016 
Rhode Island: Providence College, 2 
cases, 2015 
New Jersey: Princenton University, 9 cases, 2013-2014 
Niger:  5855 cases, Jan 1st  to May 10th 2015 
Chad: 2828 suspected cases, 135 deaths, Jan 1st to Apr 17th 2012 
Sudan: 275 suspected cases, 13 deaths, Jan 1st to  Apr 17th 2012 
Togo: 201 cases, 17 deaths, Jan 1st 2017 
Ghana: 569 suspected cases, 56 deaths, Jan 1st to Apr 17th 2012 
Burkina Faso: 5300 suspected cases, 553 deaths, Jan 1st to Apr 17th 2012 
Benin: 758 suspected cases, 71 deaths, Jan 1st to Apr 17th 2012 
New Jersey: Rutger University, 3 cases, 2016 
Nigeria:  468 cases, Dec 13th 2016 to Jun 2nd 2017 
Cote D’Ivore: 399 suspected cases, 49 deaths, Jan 1st to Apr 17th 2012 

Table 1.  Immunogenicity and safety data from pivotal phase II/III studies for novel recombinant B-MD vaccines  
Author, vaccine, study design Immunogenicity Safety Concomitant vaccines 
Gossger N, et al. 4CMenB 53 
Phase IIb, multicenter, open-
label, parallel group, 
randomized controlled trial; 
infants 2 months of age 
including two different 3 +1 
schedules (sole or co-
administered with routine 
vaccines); N=1,885  
After priming > 99% reached 
protective titers (hSBA > 5) against 
Nad A, fHbp; and 79 - 86,1% for 
PorA tests strains.  
 
Immune responses were non-
inferior by concomitant 
vaccination; and its 
immunogenicity was non-inferior to 
routine vaccines alone for all 
antigens. 
 
Sole administration elicited higher 
hSBA GMTs for all strains 
compared to coadministration with 
routine vaccines; 2,4, and 6-month 
schedule, rather than an accelerated 
2-, 3-, and 4-month schedule, 
resulted in higher hSBA GMTs for 
the Nad A test strain. 
 
Fever was more frequent after 
4CMenBdoses (26%-41%) compared 
with routine vaccines (23%-36%); 
severe erythema, swelling, or 
induration were seen in < 1%; severe 
pain was registered in 16% in the 
accelerated groups. 
PCV7 and DTaP-HBV-IPV/Hib 
No evidence of immune 
interference, except for pertactin 
and pneumococcal serotype 6B, 
of unlikely clinical significance.  
Increase in reactogenicity in the 
coadministration group, mainly 
fever (51%-61%) and severe 
pain at the injection site (12%). 
Vesikari T, et al, 4CMenB 52 
Phase III, multicenter, 
randomized, open label for 
immunogenicity and observer 
blind for safety; infants 2 – 12 
months of age; 3 +1 schedule  
N= 3,360  
After priming 100% reached hSBA 
≥ 5 against fHbp and Nad A, and 
84% for New Zealand OMV and 
NHBA tests strains. 
After booster dose: 95−100% of 
children had hSBA ≥ 5 for all 
antigens. 
Fever, injection-site reactions and 
tenderness were the most frequent 
adverse events reported 
Fever: usually on day 1, returning to 
normal by day 3.  
Injection-site reactions: peaked on 
day 1, with a steep decrease on day 2 
and lower incidence after booster. 
PCV7 and DTaP-HBV-
IPV/Hib; MMRV 
No evidence of immune 
interference, except for 
poliovirus type 2 responses, 
with unknown clinical 
significance. 
Increase in reactogenicity in the 
coadministration group; mainly 
fever (77% vs. 45%). 
 Martinón-Torres F, et al, 
4CMenB 50 
Phase IIIb, multicenter, 
randomized, open-label; healthy 
subjects from 2 ½ months to 10 
years old, divided in four 
groups:  
Group 1: doses at 2½, 3½, and 
5 + 11 months of age;   
Group 2: doses at 3½ and 5 + 
11 months of age; 
Group 3: dose at 6 and 8 + 11 
months of age.  
Group 4: 2-dose-catch-up 
series, administered 2 months 
apart. 
 
N= 754 infants and 404 
children 
After priming for groups 1 to 3, and 
after the catch up series for group 4 
100% and 99% reached hSBA ≥ 4 
against fHbp and Nad A; 
After primary/catch-up series hSBA 
≥ 4 against Por A was reached in 
groups 1,3 and 4 in 99% and in 
98% for group 2.   
NHBA 1 month after 
primary/catch-up series reached 
59% for group 1, 49% for group 2, 
77% for group 3, and  95% for 
group 4 
After booster response (measured in 
groups 1,2 and 3) 100% reached  
hSBA titers > 4 for fHbp and Nad 
A, >99% for Por A  
NHBA reached hSBA titers > 4 in 
84%, 88% and 87% in groups 1, 2 
and 3 respectively.    
In infants local tenderness, erythema 
and pain were the most commonly 
reported adverse effects  
 
Rates of systemic adverse reactions 
in infants were similar across the 3 
groups and highest after the first 
vaccination.  Across all groups, no 
increased reactogenicity was 
observed following subsequent 
vaccinations 
None 
Santolaya ME, et al., 4CMenB 
54 
Phase IIb/III, multicenter, 
randomized, observer-blind, 
placebo-controlled study; 
adolescents from 11 to 17 years 
old; 1, 2 or 3 dosing schedule 
with 1,2 and/or 6 month 
intervals; N= 1,631  
After 1 dose: 92–97% had hSBA 
titers ≥ 4 against  test strains   
After 2 or 3 doses: 99–100% had 
hSBA titers ≥ 4  against  test 
strains; reaching seroresponse rates 
of 99–100% for each strain at 6 
months. 
A third dose had a small 
incremental effect on geometric 
mean titers, especially when given 
at 6 months, but did not increase the 
Local and systemic reaction rates 
were similar after each injection and 
did not increase with subsequent 
doses, but remained higher than 
placebo.  
Pain was reported in 86% of which 
17% was severe, most resolving at 
day 3; malaise: 51%; headache: 42% 
and fever: 4%; all the above were 
statistically significant compared to 
placebo. 
No vaccine-related SAEs were 
None 
proportion of participants achieving 
protective titers 
reported and no significant safety 
signals were identified. 
 
Vesikari T, el al. rLP2086 63 
Phase II, randomized, 
multicenter, single-blind study; 
adolescents from 11 – <19 
years old; 2- or 3-dose 
schedules (0,1,6-month; 0,2,6-
month; 0,2-month; 0,4-month; 
0,6-month); N= 1,713  
 
Participants whom elicited hSBA 
titers ≥1: 8 for serogroup B test 
strains expressing vaccine-
heterologous fHbp variants A22, 
A56, B24, and B44: After 2 doses: 
90-93%, 98-100%, 69-81%, and 
70-77% . 
After 3 doses: 92-95%, 98-99%, 
88-89%, and 86-88% . 
GMTs were similar between the 2- 
and 3-dose regimens.  
Pain at the injection site, redness and 
swelling were the most common 
reactions and were mild to moderate. 
Severe pain was reported by 9.9% of 
subjects  
Headache and fatigue were the most 
common systemic symptoms and 
were mild or moderate in severity. 
Fever was infrequent (1.7%–4.3%).   
There were no differences in the 
incidence of SAEs between bivalent 
rLP2086 and saline recipients.  
None 
Muse D, et al.; rLP2086 64 
Phase II, multicenter, 
randomized, active-controlled, 
observer-blinded study; 
adolescents from 10 to <13 
years old;  concomitant or 
standalone schedule:  0,2 and 6 
months; N=2,648 
 
Immune responses to MCV4 + 
Tdap + rLP2086 were non-inferior 
to MCV4 + Tdap or rLP2086 alone. 
Seroprotective hSBA (>1:4) were 
documented for 62.3%–68.0% and 
87.5%–90% of MCV4 + Tdap + 
bivalent rLP2086 recipients after 
doses 2 and 3, respectively. A ≥4-
fold rise in hSBA titers from 
baseline was achieved by 56.3% – 
64.3% and 84.0%–85.7% of 
subjects after doses 2 and 3, 
respectively. Bivalent rLP2086 
alone induced similar responses. 
Concomitant administration did not 
substantially increase reactogenicity 
compared with rLP2086 alone. 
MCV4 and Tdap  
Bivalent rLP2086 
concomitantly with MCV4 + 
Tdap met all noninferiority 
immunogenicity criteria without 
an increase in reactogenicity. 
 
Ostergaard L, et al.; rLP2086 67 
Phase III, multicenter, 
Immunogenicity data were not 
collected 
SAEs: 1.6% of rLP2086 recipients 
Medically attended AEs were similar 
None 
 4CB-MD: Bexsero®; fHbp: factor H binding protein; Nad A: neisserial adhesin A; neisseria heparin binding antigen: NHBA; OMV: outer-
membrane vesicle; hSBA: human complement serum bactericidal activity; GMTs: geometric mean titres; SAE: serious adverse events; AE: adverse 
event; SBA: serum bactericidal assays; hSBA: serum bactericidal assays using human complement; PCV7: heptavalent pneumococcal conjugate 
vaccine; DTaP-HBV-IPV/Hib: diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, inactivated poliomyelitis, hepatitis B vaccine; 
MMRV: measles, mumps, rubella, varicella; MCV4: meningococcal ACWY conjugate vaccine; Tdap: tetanus toxoid, reduced diphtheria toxoid and 





adolescents and young adults ≥ 
10 - <26 years old; 3 doses 
schedule (0, 2, and 6 months); 
N=5,712 
between rLP2086 and hepatitis A 
vaccine/placebo group (5,5% - 7%) 
and decreased after each consecutive 
dosing 
Subjects reporting ≥ 1 AE were 
greater in the rLP2086 vaccine group. 
Ostergaard L, et al.; rLP2086 68  
Phase III, multicenter, 
randomized, controlled, 
observer-blinded, adolescents 
from 10 – 18 years old and 
from 18 to 25 years old; 3 doses 
(0,2 and 6 months) 
N= 3596 adolescents (10 to 18 
years of age); 3304 young 
adults (18 to 25 years of age) 
After 2 doses hSBA titer > 4 
against each primary strain ranged 
from 56.0 to 85.3% in subjects 10 – 
18 years old and from 78.8 to 
90.2% after dose 3 
Young adults with hSBA titers > 4 
ranged from 54.6 to 85.6% and 78.9 
to 89.7%, after doses 2 and 3, 
respectively 
Composite responses after doses 2 
and 3 in adolescents were 53.7% 
and 82.7%, respectively, and those 
in young adults were 63.3% and 
84.5%, respectively 
Pain was the most common reaction 
in the two trial groups, mainly after 
dose 1, and ≤1.1% reported increased 
severity of reaction with subsequent 
doses 
Headache and fatigue were the most 
common systemic events among both 
adolescents and young adults 
None 
